Niagen Bioscience taps Evotec to advance preclinical development of NB4168 rare-disease candidate
NAGE•Niagen Bioscience selects Evotec for NB4168 preclinical work
- Niagen Bioscience selected Evotec as a contract research partner to advance preclinical development of NB4168 for Ataxia Telangiectasia.
- Evotec will run pharmacokinetic, pharmacodynamic, and bioanalytical method validation work to support IND-enabling activities.
- Work will be conducted with Niagen’s NAD Pharmaceuticals subsidiary at Evotec’s Verona, Italy site, using Evotec’s INDiGO development platform.
- Niagen cited prior nonclinical data showing higher blood exposure for NB4168 versus NR chloride, supporting its positioning as a more bioavailable candidate.
